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Key Clinical Message
We describe a rare case of homozygous inactivating calcium-sensing receptor
mutation detected during pregnancy and mimicking primary hyperparathy-
roidism. In pregnancy, the differential diagnosis of hypercalcaemia requires a
cautious approach as physiological changes in calcium homeostasis may mask
rare genetic conditions.
Keywords
Familial hypocalciuric hypercalcemia, homozygous mutation, hypercalcemia,
pregnancy.
Introduction
Hypercalcemia during pregnancy poses a high risk to
both mother and baby, and the management can be chal-
lenging. Primary hyperparathyroidism (PHPT) is the
most common cause of marked hypercalcemia in preg-
nancy [1] and may require surgery. Differential diagnosis
of hypercalcemia includes familial hypocalciuric hypercal-
cemia (FHH), a lifelong benign condition, generally deter-
mined by heterozygous inactivating mutations of the
calcium-sensing receptor (CaSR) and biochemically char-
acterized by mild hypercalcaemia, normal PTH, normal
serum phosphorus, normal Vitamin D, low calcium uri-
nary excretion. Homozygous mutations of the CaSR gene
result in neonatal severe primary hyperparathyroidism
(NSHPT), a life-threatening condition presenting within
6 months of life with severe hypercalcemia (>3 mmol/L).
Here, we present a case of novel homozygous mutation
exceptionally detected in adulthood during pregnancy
which mimicked PHPT.
Case History
In September 2012, a 28-year-old Tanzanian woman was
found to have hypercalcemia in the 16th week of her sec-
ond pregnancy and she was referred to our endocrine
clinic for appropriate evaluation. She had previously had
a healthy 3-year-old daughter born at term, following an
uneventful first pregnancy with no identified hypercal-
cemia. She did not report any calcium-related symptoms,
and she denied history of kidney stones or fractures. She
was not taking drugs that could influence her calcium sta-
tus. There was no family history of calcium disturbances
or endocrine disorders; her parents were from the same
region in Tanzania, but they were not knowingly consan-
guineous. At the time of presentation, she was clinically
well and her physical examination was unremarkable with
no neck palpable masses or lymphadenopathy. An initial
diagnostic workup demonstrated a corrected calcium of
3.01 mmol/L (normal 2.15–2.55), inappropriately “nor-
mal” PTH of 35 ng/L (10–65), vitamin D deficiency
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(<20 mmol/L), serum phosphorus of 0.7 mmol/L (0.9–1.4),
and elevated urine calcium-to-creatinine ratio (UCCR)
(0.019). Thyroid, cortisol, and renal function tests were
unremarkable. Given her young age, fasting gut peptides
and calcitonin were requested and found to be in the
normal range. The differential diagnosis included PHPT
and FHH with laboratory findings strongly suggestive of
PHPT. She was initially managed with aggressive oral
hydration and careful vitamin D supplementation, with
no improvement in biochemical status. As sestamibi scan
is contraindicated in pregnancy due to risk of irradiation,
a neck ultrasound was performed but failed to localize a
parathyroid adenoma. PHPT with possible parathyroid
hyperplasia was considered the most likely diagnosis. She
was assessed by an experienced endocrine surgeon and at
week 24 of pregnancy, underwent full parathyroid explo-
ration. Three glands were removed with a normal appear-
ing gland left in situ. Histologically, each gland showed
hyperplasia of the parathyroid tissue. The right and left
upper parathyroid glands weighed 0.16 and 0.11 g and
measured 12 9 7 9 3 and 10 9 4 9 3 mm, respectively.
The right lower parathyroid gland weighed 0.07 g and
measured 6 9 4 9 2 mm. To our surprise, postopera-
tively she remained hypercalcaemic with calcium levels
fluctuating between 2.85 and 2.98 mmol/L. No further
parathyroid intervention occurred during pregnancy. Fol-
lowing an uncomplicated delivery, her newborn was
assessed for calcium disturbance and unexpectedly found
hypercalcemic (3.07 mmol/L, normal range 1.9–2.6) with
inappropriately normal PTH (46 ng/L) and normal
UCCR. Persistent hypercalcemia, hyperplastic parathyroid
glands, and the baby’s calcium level indicated familial
hyperparathyroidism. Sequence analysis of MEN1 and
CDC73 genes did not detect a mutation. Analysis of the
CaSR gene by the polymerase chain reaction revealed ho-
mozygosity for a transition cytosine>thymine at codon
1393 resulting in the missense mutation Arginine-465-
Tryptophan in the extracellular domain of the gene
encoding the CaSR. Genetic testing also revealed that the
newborn and the first daughter were heterozygous for the
same mutation (Fig. 1). Corrected calcium, PTH, serum
P, 25-hydroxy vitamin D levels of the patient and her two
daughters are reported in the Table 1. The UCCR of the
patient after pregnancy and urine from the baby and the
previous daughter are not available.
Discussion
Our case confirms that differential diagnosis of hypercal-
cemia in pregnancy can be challenging. The patient dis-
played features more in keeping with PHPT rather than
FHH, due to the homozygous state and probably because
of the physiological changes in calcium homeostasis
occurring in pregnancy (lower intact PTH level, increased
glomerular filtration resulting in maternal hypercalciuria).
Our patient had no symptoms, but this is not surprising.
Patients with FHH or even PHPT, having moderate-
severe hypercalcaemia, may be asymptomatic [2, 3].
In hindsight, the therapeutic management of this case
could have been more conservative, but at the time of pre-
sentation, surgery was considered as a sensible approach
based on clinical judgement and current guidelines.
Hypercalcemia (over 2.85 mmol/L) in pregnancy repre-
sents a condition potentially leading to maternal compli-
cations [4] and fetal loss and the second trimester is
considered the safest time to surgically intervene. In our
patient, hypercalcemia was not identified during her first
pregnancy as calcium levels are not routinely measured
during pregnancy or in women who wish to get pregnant.
To our knowledge, this is one of very few cases of FHH in
pregnancy described in the literature [5, 6] and the first
case of homozygous CaSR mutation identified in a preg-
nant woman. The benign course and the first presentation
in adult age of this mutation suggest that this woman’s
CaSR has residual activity and hypercalcaemia was not
severe to cause life-threatening consequences. Other cases
of homozygous CaSR mutations have been diagnosed after
infancy. Some authors have proposed a spectrum of phe-
notypes in FHH and NSHPT with the effects of the muta-
tions dependent on their location [2]. We have not
carried out any in vitro (or in silico) functional analysis to
establish the nature of the missense mutation; however,
there is evidence that the position of the mutation can
predict the functional behavior of the CaSR receptor.
From an analysis of CaSR mutations with marked hyper-
calcaemia detected after infancy, it emerged that most of
these mutations are located in the extracellular domain
and are associated with a more severe hypercalcaemia than
those located in the transmembrane and intracellular
domains [2]. Loss-of-function and gain-of-function
caused by missense mutations have been described in all
CaSR domains. We believe that this mutation is an inacti-
vating mutation as the phenotype was associated with
marked hypercalcaemia and has been previously identified
as causing FHH [3]. NSHPT has been diagnosed in
patients having only one parent with FHH [7, 8] and in
families with normocalcemic parents [9].
Beyond the rarity, our case highlights that distinguish-
ing between FHH and PHPT during pregnancy can be
challenging due to marked changes in calcium homeosta-
sis and the restricted applicability of diagnostic tools.
UCCR is the biochemical index of choice to differentiate
between FHH (<0.01) and PHPT (>0.02) [10]; however,
during pregnancy, changes in maternal calcium handling
and an increased calcium excretion make CCCR a less
useful tool to distinguish between two conditions [11].
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Urinary calcium excretion has been reported to be 250%–
300% higher during pregnancy [11].
We conclude that in pregnancy, diagnosis of hypercal-
caemia requires a cautious approach and genetic tests
should be considered when UCCR is between 0.01 and
0.02.
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Table 1. Laboratory data of the patient and her two daughters.
Patient 1st daughter 2nd daughter
Corrected calcium
(mmol/L)
3.01* 2.63†† 3.07#
PTH (ng/L) 35** 28** 46**
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25-hydroxy vitamin
D (nmol/L)
<20† <20† <20†
*Normal range 2.15–2.55 mmol/L; **normal range 10–65 ng/L;
***normal range 0.9–1.4 mmol/L; †normal range>50 nmol/L; ††normal
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range 2.24–2.74 mmol/L; ##normal range 1.0–2.6 mmol/L.
ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 3
G. Maltese et al. Homozygous inactivating calcium-sensing receptor mutation identified during pregnancy
hypercalcaemia and pregnancy outcome. Society for
Endocrinology BES 2009; Harrogate, UK.
7. Marx, S. J., M. F. Attie, A. M. Spiegel, M. A. Levine, R. D.
Lasker, and M. Fox. 1982. An association between neonatal
severe primary hyperparathyroidism and familial
hypocalciuric hypercalcemia in three kindreds. N. Engl. J.
Med. 306:257–264.
8. Eftekhari, F., and D. K. Yousefzadeh. 1982. Primary
infantile hyperparathyroidism: clinical, laboratory, and
radiographic features in 21 cases. Skeletal Radiol. 8:201–
208.
9. Ujihara, M., K. Sato, T. Ohashi, N. Tomori, K. Kasono, T.
Tsushima, et al. 1991. A case of hypocalciuric
hypercalcemia without family history. Endocrinol. Jpn.
38:689–692.
10. Eastell, R., M. L. Brandi, A. G. Costa, P. D’Amour, D. M.
Shoback, and R. V. Thakker. 2014. Diagnosis of
asymptomatic primary hyperparathyroidism: proceedings
of the Fourth International Workshop. J. Clin. Endocrinol.
Metab. 99:3570–3579.
11. Seely, E. W., E. M. Brown, D. M. DeMaggio, D. K.
Weldon, and S. W. Graves. 1997. A prospective study of
calciotropic hormones in pregnancy and post partum:
reciprocal changes in serum intact parathyroid hormone
and 1,25-dihydroxyvitamin D. Am. J. Obstet. Gynecol. 176
(1 Pt 1):214–217.
4 ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Homozygous inactivating calcium-sensing receptor mutation identified during pregnancy G. Maltese et al.
